JP2021152043A5 - - Google Patents

Download PDF

Info

Publication number
JP2021152043A5
JP2021152043A5 JP2021099839A JP2021099839A JP2021152043A5 JP 2021152043 A5 JP2021152043 A5 JP 2021152043A5 JP 2021099839 A JP2021099839 A JP 2021099839A JP 2021099839 A JP2021099839 A JP 2021099839A JP 2021152043 A5 JP2021152043 A5 JP 2021152043A5
Authority
JP
Japan
Prior art keywords
group
oxygen
nitrogen
sulfur
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021099839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021152043A (ja
Filing date
Publication date
Priority claimed from JP2018543061A external-priority patent/JP6900385B2/ja
Application filed filed Critical
Publication of JP2021152043A publication Critical patent/JP2021152043A/ja
Publication of JP2021152043A5 publication Critical patent/JP2021152043A5/ja
Priority to JP2022176130A priority Critical patent/JP2023012519A/ja
Pending legal-status Critical Current

Links

JP2021099839A 2015-11-06 2021-06-16 トリテルペンサポニン類似物 Pending JP2021152043A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022176130A JP2023012519A (ja) 2015-11-06 2022-11-02 トリテルペンサポニン類似物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562252296P 2015-11-06 2015-11-06
US62/252,296 2015-11-06
US201562268837P 2015-12-17 2015-12-17
US62/268,837 2015-12-17
JP2018543061A JP6900385B2 (ja) 2015-11-06 2016-11-04 トリテルペンサポニン類似物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018543061A Division JP6900385B2 (ja) 2015-11-06 2016-11-04 トリテルペンサポニン類似物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022176130A Division JP2023012519A (ja) 2015-11-06 2022-11-02 トリテルペンサポニン類似物

Publications (2)

Publication Number Publication Date
JP2021152043A JP2021152043A (ja) 2021-09-30
JP2021152043A5 true JP2021152043A5 (https=) 2022-03-10

Family

ID=58662549

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543061A Active JP6900385B2 (ja) 2015-11-06 2016-11-04 トリテルペンサポニン類似物
JP2021099839A Pending JP2021152043A (ja) 2015-11-06 2021-06-16 トリテルペンサポニン類似物
JP2022176130A Pending JP2023012519A (ja) 2015-11-06 2022-11-02 トリテルペンサポニン類似物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018543061A Active JP6900385B2 (ja) 2015-11-06 2016-11-04 トリテルペンサポニン類似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022176130A Pending JP2023012519A (ja) 2015-11-06 2022-11-02 トリテルペンサポニン類似物

Country Status (12)

Country Link
US (5) US20180327436A1 (https=)
EP (2) EP4001290A1 (https=)
JP (3) JP6900385B2 (https=)
KR (1) KR20180077180A (https=)
CN (2) CN112812143A (https=)
AU (1) AU2016349693B2 (https=)
CA (1) CA3003483C (https=)
CL (1) CL2018001192A1 (https=)
IL (3) IL286493B (https=)
SG (2) SG10202012205XA (https=)
WO (1) WO2017079582A1 (https=)
ZA (1) ZA201802891B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112028951A (zh) * 2014-05-30 2020-12-04 索隆-基特林癌症研究协会 微小皂苷类似物、合成及其用途
CA3003483C (en) * 2015-11-06 2022-09-13 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3609505A4 (en) * 2017-04-13 2021-04-28 Adjuvance Technologies, Inc. TRITERPEN-SAPONIN SYNTHESIS, INTERMEDIATES AND COMBINATIONS OF ADJUVANCES
CN110730666A (zh) * 2017-04-25 2020-01-24 佐剂技术公司 三萜皂苷类似物
EP3618836A4 (en) 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENSAPONINALOGA
WO2019079160A1 (en) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGS
US20230128815A1 (en) * 2020-03-23 2023-04-27 Adjuvance Technologies, Inc. Adjuvant compounds, salt forms, and formulations
WO2021236809A2 (en) 2020-05-19 2021-11-25 Othair Prothena Limited Multi-epitope vaccine for the treatment of alzheimer's disease
KR20230080397A (ko) 2020-08-07 2023-06-07 오타이르 프로테나 리미티드 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신
WO2023056089A1 (en) 2021-10-03 2023-04-06 Eisai R&D Management Co., Ltd. Immunological adjuvant formulations comprising tlr4 agonist e6020
US20250025550A1 (en) * 2021-11-08 2025-01-23 Adjuvance Technologies, Inc. Adjuvant compounds and formulations
EP4190359A1 (en) 2021-12-03 2023-06-07 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Saponin-based adjuvants and vaccines
WO2023139145A1 (en) 2022-01-19 2023-07-27 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Saponin-based adjuvants and vaccines
CN117106004A (zh) * 2022-05-17 2023-11-24 北京科兴中维生物技术有限公司 三萜皂苷化合物及其制备方法及应用
WO2024218268A1 (en) 2023-04-20 2024-10-24 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Saponin derivatives as adjuvants and photoaffinity probes
WO2024261351A2 (en) 2024-05-08 2024-12-26 Vaccine Formulation Institute Ch Ltd. Immunologically active saponin fractions and adjuvant formulations

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (https=) 1974-03-12 1978-11-01
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
AU687355B2 (en) 1992-07-17 1998-02-26 Merck Sharp & Dohme Corp. Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2263455C (en) 1996-08-23 2002-10-29 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
SK283760B6 (sk) 1996-10-15 2004-01-08 The Liposome Company, Inc. Farmaceutický prostriedok na dopravu bioaktívnych látok
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
WO2000009075A2 (en) * 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
AU7085400A (en) 1999-09-02 2001-03-26 Antigenics, Inc. Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
GB0401239D0 (en) 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
BRPI0811228A2 (pt) 2007-05-24 2014-10-21 Glaxonsmithkline Biolog S A Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
CA2708716A1 (en) 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccines for malaria
JP5706815B2 (ja) 2008-04-08 2015-04-22 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ トリテルペンであるサポニン、その合成法および使用
SI2271360T1 (sl) 2008-04-16 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
AU2012255132B2 (en) 2011-05-17 2017-05-25 Soligenix, Inc. Thermostable vaccine compositions and methods of preparing same
WO2012156391A1 (en) 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
US20150037374A1 (en) 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
CN112028951A (zh) * 2014-05-30 2020-12-04 索隆-基特林癌症研究协会 微小皂苷类似物、合成及其用途
WO2016096968A1 (en) 2014-12-18 2016-06-23 Glaxosmithkline Biologicals S.A. Vaccination
CA3003483C (en) 2015-11-06 2022-09-13 Adjuvance Technologies, Inc. Triterpene saponin analogues
US11629162B2 (en) 2015-12-17 2023-04-18 Memorial Sloan-Kettering Cancer Center Triterpene saponin variants, methods of synthesis and use thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EP3609505A4 (en) 2017-04-13 2021-04-28 Adjuvance Technologies, Inc. TRITERPEN-SAPONIN SYNTHESIS, INTERMEDIATES AND COMBINATIONS OF ADJUVANCES
CN110730666A (zh) 2017-04-25 2020-01-24 佐剂技术公司 三萜皂苷类似物
EP3618836A4 (en) 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENSAPONINALOGA
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2019079160A1 (en) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGS
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
CA3157372A1 (en) 2019-11-05 2021-05-14 Adjuvance Technologies, Inc. Varicella zoster

Similar Documents

Publication Publication Date Title
US12037355B2 (en) Triterpene saponin analogues
JP2021152043A5 (https=)
JP7177082B2 (ja) トリテルペンサポニン類似物
JP2022191284A (ja) トリテルペンサポニン類似物
US20230357300A1 (en) Triterpene saponin synthesis, intermediates and adjuvant combinations
US20260115281A1 (en) Triterpene saponin analogues
HK40042493A (en) Triterpene saponin analogues
HK40016648A (en) Triterpene saponin analogues
HK40016652A (zh) 三萜皂苷类似物
HK1260769A1 (en) Triterpene saponin analogues
HK1260769B (en) Triterpene saponin analogues